Treatment of Refractory Pruritus with Dupilumab in a Patient with Dermatomyositis

Main Article Content

Nate Bowers
William Huang

Keywords

Dermatomyositis, Dupilumab

Abstract

Abstract not available.

References

1. Giris M, Durmus H, Yetimler B, Tasli H, Parman Y, Tuzun E. Elevated IL-4 and IFN-gamma Levels in Muscle Tissue of Patients with Dermatomyositis. In Vivo. Jul-Aug 2017;31(4):657-660. doi:10.21873/invivo.11108

2. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008;47(18):1593-9. doi:10.2169/internalmedicine.47.0967

3. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. Jan 2019;143(1):155-172. doi:10.1016/j.jaci.2018.08.022

4. Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. Sep 2018;179(3):669-678. doi:10.1111/bjd.16498